About SAI Parenterals
SAI Parenterals is a company based in Hyderabad (India) founded in 2001. It operates as a Managed Services and Direct-to-Consumer (D2C). SAI Parenterals has raised $5.83 million across 1 funding round from investors including Blue Lotus Capital, Samarsh Capital and Vyom Partners. The company has 235 employees as of April 09, 2024. SAI Parenterals offers products and services including Injectables, Branded Generic Formulations, and CDMO Services.
- Headquarter Hyderabad, India
- Employees 235 as on 09 Apr, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Sai Parenterals Limited
- Date of Incorporation 12 Jan, 2001
- Jurisdiction Seri Lingampally, Telangana, India
-
Annual Revenue
$11.66 M (USD)7.73as on Mar 31, 2023
-
Net Profit
$553.23 K (USD)-45.35as on Mar 31, 2023
-
EBITDA
$2.12 M (USD)15.85as on Mar 31, 2023
-
Total Equity Funding
$5.83 M (USD)
in 1 rounds
-
Latest Funding Round
$5.83 M (USD), Series A
Jul 08, 2025
-
Investors
Blue Lotus Capital
& 2 more
-
Employee Count
235
as on Apr 09, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SAI Parenterals
SAI Parenterals offers a comprehensive portfolio of products and services, including Injectables, Branded Generic Formulations, and CDMO Services.
Sterile injectables are manufactured for critical care therapies.
Generic formulations are produced for diverse therapeutic areas.
End-to-end solutions are provided for pharmaceutical manufacturing.
Funding Insights of SAI Parenterals
SAI Parenterals has successfully raised a total of $5.83M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.83 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SAI Parenterals
SAI Parenterals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Blue Lotus Capital, Samarsh Capital and Vyom Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and capital management services are provided by Samarsh Capital.
|
Locked | Locked | Locked | |
|
Independent firm managing funds and investing in small and midcap companies worldwide.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for SAI Parenterals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SAI Parenterals
Investment portfolio details for SAI Parenterals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SAI Parenterals
Detailed financials for SAI Parenterals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sai Parenterals Comparisons
Peer comparison for SAI Parenterals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SAI Parenterals
Detailed competitors of SAI Parenterals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sai Parenterals
Complete news archive for SAI Parenterals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SAI Parenterals
SAI Parenterals was founded in 2001 and raised its 1st funding round 24 years after it was founded.
SAI Parenterals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
SAI Parenterals is a funded company, having raised a total of $5.83M across 1 funding round to date.
As of Apr 09, 2024, the latest employee count at SAI Parenterals is 235.
Annual revenue of SAI Parenterals is $11.66M as on Mar 31, 2023.
Sai Parenterals Limited is engaged in the research, development, and manufacturing of pharmaceutical formulations. Operations are structured across branded generic formulations and contract development manufacturing organization (CDMO) services. The portfolio covers multiple therapeutic areas such as cardiovascular, neuropsychiatry, and respiratory health. Products are manufactured in various dosage forms including injectables, tablets, and capsules. Facilities are located in Hyderabad, Telangana, with a focus on sterile injectables for critical care. Global presence is established in regulated and semi-regulated markets across Australia, Southeast Asia, and the Middle East.
SAI Parenterals offers Injectables, Branded Generic Formulations, and CDMO Services.
SAI Parenterals has 3 investors. Key investors include Blue Lotus Capital, Samarsh Capital, and Vyom Partners.